Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932

doi:10.1038/s41375-023-01870-8

. 2023 Jun;37(6):1375-1378.

doi: 10.1038/s41375-023-01870-8. Epub 2023 Mar 25.

Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932

Reuven J Schore^{1

2}, Anne L Angiolillo^{3

4}, John A Kairalla⁵, Meenakshi Devidas⁶, Karen R Rabin⁷, Patrick Zweidler-McKay⁸, Michael J Borowitz⁹, Brent Wood¹⁰, Andrew J Carroll¹¹, Nyla A Heerema¹², Mary V Relling¹³, Johann Hitzler¹⁴, Nina S Kadan-Lottick¹⁵, Kelly Maloney¹⁶, Cindy Wang⁵, William L Carroll¹⁷, Naomi J Winick¹⁸, Elizabeth A Raetz¹⁷, Mignon L Loh^{19

20}, Stephen P Hunger²¹

Affiliations

¹ Children's National Health System, Washington, DC, USA. rschore@childrensnational.org.
² George Washington University School of Medicine and Health Sciences, Washington, DC, USA. rschore@childrensnational.org.
³ Children's National Health System, Washington, DC, USA.
⁴ George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
⁵ Department of Biostatistics, Colleges of Medicine, Public Health & Health Professions, University of Florida, Gainesville, FL, USA.
⁶ Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
⁷ Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA.
⁸ ImmunoGen, Inc., Boston, MA, USA.
⁹ Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
¹⁰ Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
¹¹ Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
¹² Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
¹³ St Jude's Children's Research Hospital, Memphis, TN, USA.
¹⁴ Hospital for Sick Children, Toronto, ON, Canada.
¹⁵ Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
¹⁶ Children's Hospital Colorado and the Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
¹⁷ Department of Pediatrics and Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
¹⁸ University of Texas Southwestern Medical Center, Dallas, TX, USA.
¹⁹ Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA.
²⁰ Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
²¹ Department of Pediatrics and the Center for Childhood Cancer Research, the Children's Hospital of Philadelphia, Philadelphia, PA, USA.

PMID: 36966262
PMCID: PMC10503688
DOI: 10.1038/s41375-023-01870-8

Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932

Reuven J Schore et al. Leukemia. 2023 Jun.

. 2023 Jun;37(6):1375-1378.

doi: 10.1038/s41375-023-01870-8. Epub 2023 Mar 25.

Authors

Affiliations

¹ Children's National Health System, Washington, DC, USA. rschore@childrensnational.org.
² George Washington University School of Medicine and Health Sciences, Washington, DC, USA. rschore@childrensnational.org.
³ Children's National Health System, Washington, DC, USA.
⁴ George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
⁵ Department of Biostatistics, Colleges of Medicine, Public Health & Health Professions, University of Florida, Gainesville, FL, USA.
⁶ Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
⁷ Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA.
⁸ ImmunoGen, Inc., Boston, MA, USA.
⁹ Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
¹⁰ Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
¹¹ Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
¹² Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
¹³ St Jude's Children's Research Hospital, Memphis, TN, USA.
¹⁴ Hospital for Sick Children, Toronto, ON, Canada.
¹⁵ Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
¹⁶ Children's Hospital Colorado and the Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
¹⁷ Department of Pediatrics and Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
¹⁸ University of Texas Southwestern Medical Center, Dallas, TX, USA.
¹⁹ Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA.
²⁰ Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
²¹ Department of Pediatrics and the Center for Childhood Cancer Research, the Children's Hospital of Philadelphia, Philadelphia, PA, USA.

PMID: 36966262
PMCID: PMC10503688
DOI: 10.1038/s41375-023-01870-8

Erratum in

Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.
Schore RJ, Angiolillo AL, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, Borowitz MJ, Wood B, Carroll AJ, Heerema NA, Relling MV, Hitzler J, Kadan-Lottick NS, Maloney K, Wang C, Carroll WL, Winick NJ, Raetz EA, Loh ML, Hunger SP. Schore RJ, et al. Leukemia. 2023 Jun;37(6):1406. doi: 10.1038/s41375-023-01921-0. Leukemia. 2023. PMID: 37157018 No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

RJS has been on an advisory board and received honoraria from Jazz Pharmaceuticals; ALA has been on an advisory board and received honoraria from Jazz Pharmaceuticals. JAK has stock in Johnson & Johnson common stock. PZM employment at ImmunoGen. MJB has been on an advisory board and received honoraria from Amgen and received honoraria from Blueprint Medicines; BW has served as a consultant for Amgen and had received research funding from Celgene/Juno, Kite, Novartis, and Wugen; NSKL has a family member who is a consultant for Medtronic and Boston scientific; MVR and her institution receive investigator-initiated funding from Servier; EAR has received institutional research funding from Pfizer and serves on a DSMB for Celgene/BMS;SPH owns common stock in Amgen and has received honoraria from Amgen, Jazz and Servier.

Figures

**Figure 1**
CONSORT Diagram of Low Risk ALL Patients Enrolled on COG AALL0932

**Figure 2:**
Survival in LR B-ALL patients from EOI by randomized treatment arm. A Five-year disease-free survival. B Five-year overall survival.

See this image and copyright information in PMC

Cited by

A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL.
Popov A, Henze G, Roumiantseva J, Bydanov O, Belevtsev M, Verzhbitskaya T, Movchan L, Tsaur G, Lagoyko S, Zharikova L, Myakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Cancers (Basel). 2023 Nov 23;15(23):5547. doi: 10.3390/cancers15235547. Cancers (Basel). 2023. PMID: 38067249 Free PMC article.
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML. Gupta S, et al. N Engl J Med. 2025 Feb 27;392(9):875-891. doi: 10.1056/NEJMoa2411680. Epub 2024 Dec 7. N Engl J Med. 2025. PMID: 39651791 Free PMC article. Clinical Trial.
Rethinking paraneoplastic eosinophilia.
Bernt KM. Bernt KM. Haematologica. 2024 Aug 1;109(8):2385-2387. doi: 10.3324/haematol.2024.285081. Haematologica. 2024. PMID: 38572550 Free PMC article. No abstract available.
Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.
Mullighan C, Wangondu R, Ashcraft E, Chang TC, Roberts K, Brady S, Fan Y, Evans W, Relling M, Crews K, Yang J, Yang W, Pounds S, Wu G, Devidas M, Maloney K, Mattano L Jr, Schore R, Angiolillo A, Larsen E, Salzer W, Burke M, Loh M, Jeha S, Pui CH, Inaba H, Cheng C. Mullighan C, et al. Res Sq [Preprint]. 2024 Nov 11:rs.3.rs-5292018. doi: 10.21203/rs.3.rs-5292018/v1. Res Sq. 2024. Update in: Leukemia. 2025 Jul;39(7):1595-1606. doi: 10.1038/s41375-025-02633-3. PMID: 39606455 Free PMC article. Updated. Preprint.
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.
Chang TC, Chen W, Qu C, Cheng Z, Hedges D, Elsayed A, Pounds SB, Shago M, Rabin KR, Raetz EA, Devidas M, Cheng C, Angiolillo A, Baviskar P, Borowitz M, Burke MJ, Carroll A, Carroll WL, Chen IM, Harvey R, Heerema N, Iacobucci I, Wang JR, Jeha S, Larsen E, Mattano L, Maloney K, Pui CH, Ramirez NC, Salzer W, Willman C, Winick N, Wood B, Hunger SP, Wu G, Mullighan CG, Loh ML. Chang TC, et al. J Clin Oncol. 2024 Oct 10;42(29):3491-3503. doi: 10.1200/JCO.23.02238. Epub 2024 Aug 9. J Clin Oncol. 2024. PMID: 39121442 Free PMC article.

See all "Cited by" articles

References

1. Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015;33(27):2938–48. - PMC - PubMed
1. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111(12):5477–85. - PMC - PubMed
1. Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977–87. - PMC - PubMed
1. Winick N, Martin PL, Devidas M, Shuster J, Borowitz MJ, Paul Bowman W, et al. Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905. Leukemia. 2020;34(4):1006–16. - PMC - PubMed
1. Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2011;118(2):243–51. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Grants and funding

U24 CA114766/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015;33(27):2938–48. - PMC - PubMed

[2] Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015;33(27):2938–48. - PMC - PubMed

[3] Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111(12):5477–85. - PMC - PubMed

[4] Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111(12):5477–85. - PMC - PubMed

[5] Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977–87. - PMC - PubMed

[6] Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977–87. - PMC - PubMed

[7] Winick N, Martin PL, Devidas M, Shuster J, Borowitz MJ, Paul Bowman W, et al. Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905. Leukemia. 2020;34(4):1006–16. - PMC - PubMed

[8] Winick N, Martin PL, Devidas M, Shuster J, Borowitz MJ, Paul Bowman W, et al. Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905. Leukemia. 2020;34(4):1006–16. - PMC - PubMed

[9] Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2011;118(2):243–51. - PMC - PubMed

[10] Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2011;118(2):243–51. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932

Affiliations

Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932

Authors

Affiliations

Erratum in

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources